The Tale of Two TLR7/8 Inhibitors at EULAR 2025: Enpatoran and Afimetoran
Data presented today
The recent EULAR 2025 congress in Barcelona has been a hotbed of innovation, particularly in the challenging landscape of Systemic Lupus Erythematosus (SLE). Among the most anticipated data were presentations on a promising class of molecules: oral Toll-like receptor 7 and 8 (TLR7/8) inhibitors. Two companies, Merck KGaA and Bristol Myers Squibb, presented compelling, yet distinct, narratives for their respective candidates, enpatoran and afimetoran.
These presentations offer a fascinating glimpse into the journey of drug development, from elucidating the mechanism to navigating the complexities of Phase II clinical trials. For those of us dedicated to bringing new therapies to patients, they provide critical insights into a pathway implicated in the core pathogenesis of lupus.
Merck's Enpatoran: Navigating the Nuances of Clinical Efficacy
Merck presented data from Cohort B of the WILLOW study, a Phase II, randomized, placebo-controlled trial of enpatoran in patients with active SLE. This was a significant moment, as it moved the TLR7/8 hypothesis into the crucible of clinical testing in a broad SLE population.
The results, however, were not straightforward and highlight the well-known challenges of developing drugs for this heterogeneous disease.
The Primary Endpoint: The study did not meet its primary objective of demonstrating a statistically significant dose-response relationship for the BICLA composite endpoint at week 24. This is, on the surface, a setback and a critical finding to acknowledge.
Encouraging Signals Emerge: Although the data missed the primary endpoint, it reveals a more complex and ultimately promising picture.
All enpatoran dose groups showed numerically higher BICLA response rates compared to the placebo.
Notably, the lowest dose of 25 mg twice daily (BID) achieved nominal statistical significance compared to placebo (p = 0.0088).
Crucially, the drug demonstrated clear evidence of target engagement. It significantly reduced the type I interferon gene signature (IFN-GS) from as early as week 2, confirming the role of the TLR7/8 pathway in this key inflammatory cascade in SLE.
The most significant treatment effects were seen in patients with a high IFN-GS at baseline and in those receiving higher daily doses of glucocorticoids (>=10 mg prednisone equivalent), suggesting a path forward through targeted patient selection.
Steroid-Sparing and Cutaneous Benefits: The trial showed that higher rates of BICLA response combined with meaningful steroid reduction were observed across all enpatoran groups compared to placebo. Furthermore, in patients with significant skin involvement, enpatoran led to substantial improvements in CLASI scores.
Safety Profile: The safety and tolerability data were very encouraging. There was no clinically meaningful difference in the rates of treatment-emergent adverse events (TEAEs) between enpatoran and placebo, and no evidence of a dose-dependent increase in side effects.
The enpatoran story is a classic example of a nuanced Phase II outcome. While the dose-response curve was not established, the clear biological activity and strong signals in specific, high-need patient populations provide a solid rationale for further development.
BMS's Afimetoran: Unraveling the "Why" of Steroid-Sparing
In contrast to Merck's clinical data, Bristol Myers Squibb presented preclinical and translational data for its TLR7/8 antagonist, afimetoran. Their work focuses on a critical question: how does TLR7/8 inhibition potentiate the effects of glucocorticoids? Current treatments often require high steroid doses, which carry a heavy burden of long-term toxicity.
BMS provided compelling evidence that afimoteran could be a potent steroid-sparing agent, offering a deeper look into the underlying mechanisms.
A Mechanistic Explanation: The core of their findings is that afimetoran sensitizes key immune cells to the effects of steroids. In vitro, the addition of afimetoran led to a notable increase in prednisolone-induced apoptosis (programmed cell death) of plasmacytoid dendritic cells (pDCs) and B cells—two cell types central to lupus pathology.
Translational Confirmation: This effect was observed in whole blood samples from patients with SLE, where afimetoran, both alone and with prednisolone, suppressed inflammatory cytokines. This provides a direct translational link between the lab and the patient.
In Vivo Proof-of-Concept: The benefits were further demonstrated in a mouse model of spontaneous lupus.
Afimetoran treatment significantly reduced kidney injury markers, autoantibody titers, and inflammatory cytokines.
Notably, the combination of afimetoran with prednisolone showed greater suppression of these disease markers than either treatment alone, demonstrating true synergy.
The afimetoran data provides a powerful mechanistic rationale for the steroid-sparing effects seen clinically with enpatoran. It suggests that blocking TLR7/8 may not only reduce innate immune activation but also resensitize the immune system to the effects of glucocorticoids, a potential paradigm shift in managing lupus.
Synthesis and a Look to the Future
Juxtaposing these two presentations from EULAR 2025 provides a holistic view of the TLR7/8 inhibitor class.
Merck's Enpatoran provides human clinical data, along with its inherent complexities. It demonstrates that the drug is biologically active and shows promise in identifiable patient subgroups, although without a clear dose-response relationship. The favorable safety profile is a significant asset.
BMS's afimetoran provides the elegant mechanistic backstory. It explains why a TLR7/8 inhibitor should work, particularly in concert with steroids, and its preclinical data strongly support the viability of this target.
The challenge for Enpatoran will be to leverage the subgroup findings to design a successful Phase III program. The nominal efficacy of the lowest dose requires further exploration. For afimetoran, the challenge will be to translate its beautiful preclinical and mechanistic story into the messy reality of a large-scale clinical trial.
Ultimately, both abstracts underscore that TLR7/8 inhibition is an auspicious and scientifically rational approach for treating SLE. The path forward is not without its hurdles, but the data presented at EULAR gives us renewed confidence that we are moving closer to offering patients more effective and safer therapeutic options that could reduce their debilitating reliance on long-term steroids.